Skip to Content

SELLAS Life Sciences Group Inc SLS Stock Quote

| Rating as of


Morningstar‘s Stock Analysis SLS

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SLS

Company Profile SLS

Business Description

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Its product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The company is also developing GFH009, a small molecule, CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai) Inc, for all therapeutic and diagnostic uses in the world outside of Greater China.

7 Times Square, Suite 2503
New York, NY, 10036
T +1 646 200-5278
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 11